Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index; 23 of the 25 sources its claims cite were checked for support.
Abstract
Background Patients who have had an acute coronary syndrome are at high risk for recurrent ischemic cardiovascular events. We sought to determine whether alirocumab, a human monoclonal antibody to proprotein convertase subtilisin–kexin type 9 (PCSK9), would improve cardiovascular outcomes after an acute coronary syndrome in patients receiving high‐intensity statin therapy. Methods We conducted a multicenter, randomized, double‐blind, placebo‐controlled trial involving 18,924 patients who had an acute coronary syndrome 1 to 12 months earlier, had a low‐density lipoprotein (LDL) cholesterol level of at least 70 mg per deciliter (1.8 mmol per liter), a non‐high‐density lipoprotein cholesterol level of at least 100 mg per deciliter (2.6 mmol per liter), or an apolipoprotein B level of at least 80 mg per deciliter, and were receiving statin therapy at a high‐intensity dose or at the maximum tolerated dose. Patients were randomly assigned to receive alirocumab subcutaneously at a dose of 75 mg (9462 patients) or matching placebo (9462 patients) every 2 weeks. The dose of alirocumab was adjusted under blinded conditions to target an LDL cholesterol level of 25 to 50 mg per deciliter (0.6 to 1.3 mmol per liter). The primary end point was a composite of death from coronary heart disease, nonfatal myocardial infarction, fatal or nonfatal ischemic stroke, or unstable angina requiring hospitalization. Results The median duration of follow‐up was 2.8 years. A composite primary end‐point e…
Overview
CoChat Summary
TL;DR
In patients with a recent acute coronary syndrome receiving high-intensity or maximum-tolerated statin therapy, alirocumab reduced the risk of recurrent ischemic cardiovascular events compared with placebo. The benefit was driven mainly by the composite primary end point, with similar adverse-event rates except for more local injection-site reactions.
Key findings
- The primary composite end point occurred in 903 patients (9.5%) in the alirocumab group vs. 1052 patients (11.1%) in the placebo group (hazard ratio, 0.85; 95% CI, 0.78 to 0.93; P<0.001); the 4-year Kaplan-Meier estimate was 12.5% vs. 14.5%, and 49 patients would need treatment for 4 years to prevent one primary event.
- Death from any cause occurred in 334 patients (3.5%) in the alirocumab group vs. 392 patients (4.1%) in the placebo group (hazard ratio, 0.85; 95% CI, 0.73 to 0.98).
- Absolute benefit was greater among patients with baseline LDL cholesterol ≥100 mg/dL; in that nonprespecified subgroup, 16 patients (95% CI, 11 to 34) would need treatment for 4 years to prevent one primary event (P<0.001 for interaction).
- Adverse events were similar between groups except local injection-site reactions, which occurred in 3.8% of alirocumab patients vs. 2.1% of placebo patients (P<0.001).
Methods
- Multicenter, randomized, double-blind, placebo-controlled trial enrolling 18,924 patients who had an acute coronary syndrome 1 to 12 months earlier and elevated atherogenic lipid levels despite high-intensity or maximum-tolerated statin therapy.
- Patients were randomly assigned 1:1 to subcutaneous alirocumab 75 mg every 2 weeks (9462 patients) or matching placebo (9462 patients), with blinded dose adjustment targeting LDL cholesterol 25 to 50 mg/dL.
- The primary end point was a composite of death from coronary heart disease, nonfatal myocardial infarction, fatal or nonfatal ischemic stroke, or unstable angina requiring hospitalization; median follow-up was 2.8 years, with intention-to-treat Cox proportional-hazards analysis stratified by geographic region.
Limitations
- The paper states that a limitation of all three PCSK9 antibody trials, including this one, is infrequent use of ezetimibe because its cardiovascular efficacy was established after most patients had already been enrolled.
- The paper states that whether safety and efficacy were influenced by the blinded dose-adjustment strategy is unknown, and that neither this trial nor FOURIER can fully predict longer-term safety of PCSK9 monoclonal antibody treatment.
- Evident from the text: median follow-up was 2.8 years, limiting assessment of longer-term outcomes; the baseline LDL cholesterol ≥100 mg/dL subgroup finding was from a nonprespecified analysis.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
15 Valid · 1 Not valid · 3 Not checked · 54 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“These findings have led to the development of monoclonal antibodies to PCSK9 that produce substantial reductions in LDL cholesterol when administered alone or with a statin. 8-12”
What the sources say
- Supportedcites [8] 8. Stein EA, Mellis S, Yancopoulos GD, et al. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N Engl J Med 2012; 366: 1108-18. source
The Discussion (page not supplied) states that REGN727 lowered LDL cholesterol both alone and in subjects already receiving atorvastatin. The Lipid and Lipoprotein Response section reports substantial reductions in the atorvastatin-treated groups. (LLM, conf=0.93)
- Could not verifycites [9] 9. Robinson JG, Farnier M, Krempf M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 2015; 372: 1489-99. sourceExperimental — accuracy not yet measured
The supplied copy contains repository metadata and a PDF listing, but no passage reporting LDL-cholesterol outcomes (Abstract listing). Searches for PCSK9 antibodies, alirocumab, LDL reduction, and use with or without a statin returned no matching passages. The claim therefore cannot be checked against our copy. (LLM, conf=0.78)
- Supportedcites [10] 10. Blom DJ, Hala T, Bolognese M, et al. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med 2014; 370: 1809-19. source
The Efficacy End Points section reports substantial LDL-cholesterol reductions with the PCSK9 monoclonal antibody evolocumab both in the diet-alone group and in groups receiving atorvastatin. The paper also describes earlier trials of PCSK9 inhibitors that significantly reduced LDL cholesterol. (LLM, conf=0.92)
- Supportedcites [11] 11. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017; 376: 1713-22. source
The Introduction (p. 1714) says PCSK9 monoclonal antibodies effectively lower LDL cholesterol and that evolocumab reduces it by approximately 60%. Its cited studies include both an anti-PCSK9 monotherapy trial and a trial adding evolocumab to statin therapy (References); the Discussion also reports a 59% reduction with statin therapy. (LLM, conf=0.88)
- Supportedcites [12] 12. Sabatine MS, Giugliano RP, Wiviott SD, et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med 2015; 372: 1500-9. source
The paper describes PCSK9 monoclonal antibodies as very effective at lowering LDL cholesterol. Its End Points table includes evolocumab trials with no background lipid therapy and trials with statins; the Lipid Changes section reports a 61% LDL-cholesterol reduction with evolocumab versus standard therapy at 12 weeks. The reported reduction is pooled, not a separate estimate for each treatment setting. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Patients who have had an acute coronary syndrome are at high risk for recurrent ischemic cardiovascular events.”
What the sources say
- Partly supportedcites [1] 1. Fox KA, Goodman SG, Klein W, et al. Management of acute coronary syndromes - variations in practice and outcome; findings from the Global Registry of Acute Coronary Events (GRACE). Eur Heart J 2002; 23: 1177-89. sourceExperimental — accuracy not yet measured
The Results section (p. 1181) reports in-hospital reinfarction after acute coronary syndrome, supporting a risk of recurrent events during admission. The paper says six-month outcomes were collected (Data collection), but it does not report those results here, so it does not establish a high risk of recurrent events after discharge. (LLM, conf=0.80)
- Partly supportedcites [2] 2. Jernberg T, Hasvold P, Henriksson M, Hjelm H, Thuresson M, Janzon M. Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a longterm perspective. Eur Heart J 2015; 36: 1163-70. sourceExperimental — accuracy not yet measured
The Results report an 18.3% one-year risk of MI, stroke, or cardiovascular death after an index MI, and the Discussion says risk remained high in subsequent years. This supports the claim for patients after MI, but the study does not establish the same risk for all patients after acute coronary syndrome, a broader group. (LLM, conf=0.84)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Similarly, a recent meta-analysis showed that intensive lowering of LDL cholesterol (primarily with the use of statins) resulted in a mortality benefit that was observed only among patients with a baseline LDL cholesterol level of 100 mg or more per deciliter. 20”
What the sources say
- Supportedcites [20] 20. Navarese EP, Robinson JG, Kowalewski M, et al. Association between baseline LDL-C level and total and cardiovascular mortality after LDL-C lowering: a systematic review and meta-analysis. JAMA 2018; 319: 1566-79. source
The All-Cause Mortality and Cardiovascular Mortality sections report mortality risk reductions with more intensive LDL-C lowering only in trials with baseline LDL-C levels of at least 100 mg/dL. The Study Selection and Patient Population section reports that 26 of the 34 trials used statin monotherapy, supporting “primarily with statins.” The threshold describes trial-level baseline LDL-C, rather than a demonstrated cutoff for individual patients. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“A limitation of all three trials is the infrequent use of ezetimibe, for which cardiovascular efficacy was established 5 after most of the patients had already been enrolled and the trials were well under way.”
What the sources say
- Supportedcites [5] 5. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015; 372: 2387-97. source
The citation is attached to the assertion that ezetimibe’s cardiovascular efficacy was established. The Conclusions report improved cardiovascular outcomes when ezetimibe was added to statin therapy, and the Efficacy End Points section reports significantly fewer cardiovascular events. The timing relative to the citing authors’ three trials is their own framing, not a finding attributed to this source. (LLM, conf=0.91)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The current trial and the FOURIER trial showed similar improvements in composite cardiovascular outcomes with PCSK9 inhibition among patients who had a baseline LDL cholesterol level of 70 mg or more per deciliter and whose average baseline LDL cholesterol level was approximately 90 mg per deciliter. 10”
What the sources say
- Partly supportedcites [10] 10. Blom DJ, Hala T, Bolognese M, et al. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med 2014; 370: 1809-19. sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 1 unverifiable. Expand the claim to see per-atom verdicts.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
24 more claims · 3 with their cited sources checked
Create a free account to see all 73 claims and every source verdict.
- Probably not a substantial claim. 20
- It may state two separate claims as one. 27
- The quote only partly states this claim. 4
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the cumulative data from the FOURIER and ODYSSEY OUTCOMES trials suggest that PCSK9 inhibitors effectively lower LDL-C and cardiovascular risk in individuals with CAD regardless of diabetes mellitus status.”
From Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association (2020) · cites this paper as [126]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Two RCTs have reported a beneficial effect on clinical endpoints in ASCVD patients without FH [119,120].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [119]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The mAb PCSK9 inhibitors evolocumab and alirocumab lower LDLC levels by ∼60% and, when added to statin therapy, decrease the risk of major vascular events [119].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [119]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the FOURIER trial, which included 27 564 patients with atherosclerotic CV disease, the addition of evolocumab to statin therapy (69% high-intensity therapy) resulted in a 15% relative risk reduction of the composite primary endpoint throughout a 2.2 year follow-up.”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [119]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, the best evidence to support lower LDL cholesterol targets in people with diabetes and established cardiovascular disease derives from multiple large randomized trials investigating the benefi ts of adding nonstatin agents to statin therapy.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [110]
Experimental — accuracy not yet measured
32 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Patients, Trial Regimen, and Follow-up
“In China, 613 patients underwent randomization from May 2016 through February 2017.”
§ Statistical Analysis
“In China, 614 patients underwent randomization after random assignment of the main trial cohort had been completed”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“| Missing data | 19 (<0.1) | 12 (<0.1) |”
Reported 0.1 · recomputed 0.200803
Citations
Cites
Ibanez, B., James, S., Agewall, S., Antunes, M. J., Bucciarelli-Ducci, C., Bueno, H., Caforio, A. L. P., Crea, F., Goudevenos, J. A., Halvorsen, S., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx393 · Cited by 9,728
Self-citationRoffi, M., Patrono, C., Collet, J.-P., Mueller, C., Valgimigli, M., Andreotti, F., Bax, J. J., Borger, M. A., Brotons, C., Chew, D. P., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv320 · Cited by 8,261
Self-citationEvolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Sabatine, M. S., Giugliano, R. P., Keech, A. C., Honarpour, N., Wiviott, S. D., Murphy, S. A., Kuder, J. F., Wang, H., Liu, T., Wasserman, S. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615664 · Cited by 6,138
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487
Self-citation2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes
Amsterdam, E. A., Wenger, N. K., Brindis, R. G., Casey, D. E., Ganiats, T. G., Holmes, D. R., Jaffe, A. S., Jneid, H., Kelly, R. F., Kontos, M. C., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.09.017 · Cited by 3,595
Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
Abifadel, M., Varret, M., Rabès, J.-P., Allard, D., Ouguerram, K., Devillers, M., Cruaud, C., Benjannet, S., Wickham, L., Erlich, D., et al. (2003) · Nature Genetics · doi:10.1038/ng1161 · Cited by 2,985
2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction
O'Gara, P. T., Kushner, F. G., Ascheim, D. D., Casey, D. E., Chung, M. K., de Lemos, J. A., Ettinger, S. M., Fang, J. C., Fesmire, F. M., Franklin, B. A., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.11.019 · Cited by 2,625
Schwartz, G. G. (2001) · JAMA · doi:10.1001/jama.285.13.1711 · Cited by 2,499
Self-citation
Cited by
Items 2,301–2,400 of 3,636
Ахмеджанов, Н. М., Небиеридзе, Д. В., & Safaryan, A. S. (2019) · Rational Pharmacotherapy in Cardiology · doi:10.20996/1819-6446-2018-14-6-917-921 · Cited by 3
Alirocumab and evolocumab: an indirect comparison of cardiovascular benefits
Siasos, G., Oikonomou, E. K., & Tousoulis, D. (2020) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvaa031 · Cited by 3
Sabatine, M. S., Giugliano, R. P., & Schwartz, G. G. (2021) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2021.1874346 · Cited by 3
Self-citationEditorial commentary: A new era for preventive cardiology
Clarke, S. L. (2021) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2021.04.007 · Cited by 3
Circulating levels of PCSK9, ANGPTL3 and Lp(a) in stage III breast cancersPreprint
Chong, E. W., Joncas, F., Seidah, N. G., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1420016/v1 · Cited by 3
Brinck, A. P. J., Hagström, A. P. E., Nåtman, J., Franzén, S., Eeg‐Olofsson, K., Nathanson, A. P. D., & Eliasson, B. (2022) · doi:10.2337/figshare.21224384 · Cited by 3
Gobeil, É., Bourgault, J., Mitchell, P. L., Houessou, U., Gagnon, É., Girard, A. S., Paulin, A., Manikpurage, H. D., Couture, C., Marceau, S., et al. (2023) · medRxiv · doi:10.1101/2023.05.29.23290580 · Cited by 3
Ference, B. A., Ference, T. B., Catapano, A. L., Nicholls, S. J., & Ray, K. K. (2024) · medRxiv · doi:10.1101/2024.06.30.24309740 · Cited by 4
A Step Forward for Long-Acting PCSK9 Inhibition
Santos, R. D., Nasir, K., & Shapiro, M. D. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.09.019 · Cited by 3
Hamad, M. A., Muhammad, J. S., Rah, B., Hasan, H. A., Taneera, J., Soofi, A., & Awadallah, S. M. (2023) · Advanced Therapeutics · doi:10.1002/adtp.202300107 · Cited by 3
López, A. A. P., Chávez-Negrete, A., Rodríguez-Lozano, A. L., Gómez-Alarcón, Á. J., Montaño-Velázquez, B. B., Hinojosa, C. A., Sánchez-Hernández, C., Pimentel-Hernández, C., Dehesa-López, E., Romero-Moreno, F., et al. (2026) · Revista Mexicana de Endocrinología Metabolismo y Nutrición · doi:10.24875/rme.m23000030 · Cited by 9
When Does Primary Prevention Encroach on Secondary Prevention?
Deshotels, M. R., Kotta, P. A., Mesa, J. S. R., Oyenubi, O., & Nambi, V. (2024) · Current Atherosclerosis Reports · doi:10.1007/s11883-024-01227-1 · Cited by 2
“…Outcomes After an Acute Coronary Syndrome During Treatment with Alirocumab) and FOURIER (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk) provide a contemporary framework for cardiovascular risk among secondary prevention patients [10, 11].”
Hu, E., & Wan, M. (2024) · Coronary Artery Disease · doi:10.1097/mca.0000000000001464 · Cited by 4
Bempedoic Acid: A Review in Cardiovascular Risk Reduction in Statin-Intolerant Patients
McGuigan, A., & Blair, H. A. (2025) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-024-00714-9 · Cited by 4
Alraddadi, S. I., Almodaimegh, H., Kharbosh, A., Alharbi, H., Fathelrahman, A. I., Alsheikh, M. Y., & Alfehaid, L. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01587-x · Cited by 4
Tu, K.-C., Chang, W., Lin, H.-W., Lin, P., Wu, Y., Lin, C., Yeh, H., Charng, M., Huang, P., Lin, T., et al. (2025) · European journal of medical research · doi:10.1186/s40001-025-02431-8 · Cited by 2
Nägele, M. P., Raemy, Y., Kreysing, L., et al. (2025) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.03.006 · Cited by 2
Xiong, Q., Tremblay, F., & Marlowe, J. L. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.04.012 · Cited by 2
NOACK, F., Eckrich, K., Völler, H., Schwaab, B., Heinze, V., Bongarth, C., Guha, M., Richter, M., Schwark, N., Strobel, A., et al. (2025) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2025.1549935 · Cited by 3
An evaluation of recaticimab for the treatment of hypercholesterolemia
Tang, X. L., Hooper, A. J., & Burnett, J. R. (2025) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2025.2508837 · Cited by 2
“Alirocumab demonstrated a similar percentage reduction in LDL-cholesterol and rate of MACE [5,8].”
PCSK9-Targeting Drugs and Gender: Are There Any Differences?
Liberati, V., Guidotti, G., Sorrentino, A., Slanzi, M., Lotti, E., Crudele, F., Rogolino, A. A., Alfano, F., Giusti, B., Gori, A. M., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14134469 · Cited by 4
“Trials have demonstrated that PCSK9 inhibitors—both antibodies and inclisiran—can achieve about a 50% reduction in LDL-C, resulting in improved cardiovascular prognosis and reduced mortality [23,24].”
Addressing Disparities in the Screening and Treatment of Dyslipidemia – A Call to Action
Converse, E., Watson, K., Ahmad, Z., Yang, E., Gianos, E., Sagheer, U., Virani, S. S., & Kalra, D. K. (2025) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-025-00769-6 · Cited by 2
“In both ODESSEY and FOURIER trials that established the efficacy of PCSK9i, females accounted for approximately 25% of participants, and White adults accounted for approximately 79% and 85% of participants, respectively [205, 206].”
Qi, L., Shen, H., Chai, M., Chen, B., He, Y., Shi, X., Lian, Q., Wang, Z., Qu, Y., Qian, L., et al. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02816-3 · Cited by 3
Korneva, V. A., & Kuznetsova, T. Y. (2025) · Kardiologiia · doi:10.18087/cardio.2025.6.n2950 · Cited by 3
Using Large Genomic Biobanks to Generate Insights into Genetic Kidney Disease
Chang, A. R., Wongboonsin, J., Mallett, A. J., Morales, A., Retterer, K., Mirshahi, T., & Sayer, J. A. (2025) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2025.151651 · Cited by 3
Wu, X., Zhu, X., Fang, M., Qi, F., Yin, Z., Zhang, J. Z. H., Luo, S., Zhu, T., & Gao, Y. (2025) · Molecules · doi:10.3390/molecules30142962 · Cited by 7
“Notably, Alirocumab and Evolocumab have received FDA approval for the treatment of heterozygous familial hypercholesterolemia (HeFH) [17].”
Parhofer, K. G., Pittrow, D., Birkenfeld, A. L., Fraass, U., Hohenstein, B., Siegert, C., Klotsche, J., Steinhagen‐Thiessen, E., Dexl, S., Schettler, V. J. J., et al. (2025) · Clinical Research in Cardiology · doi:10.1007/s00392-025-02719-z · Cited by 4
“Large-scale outcome trials have confirmed that these antibodies significantly reduce CV risk in patients with atherosclerotic CV disease (ASCVD) [4, 5].”
Medical Management of Coronary Artery Disease: An Update
Hullon, D., Bilal, M., & Shammas, N. W. (2025) · International Journal of Angiology · doi:10.1055/a-2645-8838 · Cited by 5
Kolios, N.-G., Barkas, F., Ntaios, G., & Milionis, H. J. (2025) · Thrombosis and Haemostasis · doi:10.1055/a-2675-0551 · Cited by 5
Event Reduction With Obicetrapib
Bittner, V. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.08.031 · Cited by 2
Self-citationFrom LDL-C to lipoprotein(a) - those who fail to learn from history are doomed to repeat it
Sarraju, A., & Nissen, S. E. (2025) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2025.101280 · Cited by 2
“The FOURIER and ODYSSEY-OUTCOMES trials reported unimpressive hazard ratios of 0.85 for cardiovascular event reduction despite their powerful LDL-C lowering effects [36,37].”
InfluentialJaiswal, V., Goyal, A., Deb, N., Shama, N., Mittal, V., Rajak, K., Halder, A., Khadka, S., Kumar, T., Ahmed, R., et al. (2025) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2025.101311 · Cited by 3
“They effectively lower low-density lipoprotein cholesterol (LDL-C) concentration and significantly reduce cardiovascular disease (CVD) events in high-risk patients on statin therapy[1].”
Gao, A., Guo, T., Yang, Z., Qiu, H., & Gao, R. (2025) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm36438 · Cited by 4
“Aggressive lipid-lowering therapies have produced positive results and further reduced adverse event rates by 2–15% [5,23,24].”
Nonanticoagulant Strategies for Venous Thromboembolism Prophylaxis
Gurumurthy, G., & Thachil, J. V. (2025) · Seminars in Thrombosis and Hemostasis · doi:10.1055/a-2712-3534 · Cited by 5
Morieri, M. L., Longato, E., Sciannameo, V., Donatiello, E., Berchialla, P., Avogaro, A., Consoli, A., & Fadini, G. P. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02952-w · Cited by 3
“For example, re-analyses of the effects of PCSK9 inhibitors stratified by LDL-cholesterol levels [30, 31], and of the effect of the combination aspirin/ rivaroxaban stratified by diabetes status [32] showed significant differences in the ARR across groups even with similar HR.”
Cabezas, M. C., Orsini, M., Tokgözoğlu, L., Marx, N., Tuñón, J., Vrablík, M., Tavori, H., Bhatt, D. L., & Filardi, P. P. (2025) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.10.062 · Cited by 2
Self-citationKathariya, G., Aggarwal, J., Nandal, R., & Reddy, S. (2025) · Heart India · doi:10.4103/heartindia.heartindia_77_25 · Cited by 2
Rai, H., Coughlan, J. J., O’Callaghan, D., Sheahan, R. G., Murphy, R. T., Burke, D., McFadden, E. P., Nolan, D., Colleran, R., Hazeez-Agbaje, A., et al. (2025) · Irish Journal of Medical Science (1971 -) · doi:10.1007/s11845-025-04096-y · Cited by 2
Hu, M., Gong, Z., Li, X., Xia, J., & Yin, C. (2025) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.10.076 · Cited by 3
Inflammation and atherosclerotic cardiovascular disease: where do we go from here?
Waksman, O., & Waksman, R. (2025) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000001009 · Cited by 4
VESALIUS and the Anatomy of High-Risk Prevention
Ndumele, C. E., & Blumenthal, R. S. (2025) · New England Journal of Medicine · doi:10.1056/nejme2515447 · Cited by 3
Lipid lowering therapies in chronic kidney disease: A call to action
Ruiz, J. M., Arroyo, D., de Cos, M., Fernández, M. R., Sánchez-Álvarez, E., Bores, P. G., Hernández, J. L., & Corral, P. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.120563 · Cited by 4
Russo, M., Bacigalupi, E., Radico, F., Scorpiglione, L., Gurgoglione, F. L., Russo, A., Vigna, C., Galli, M., Benenati, S., Vergallo, R., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14228132 · Cited by 2
“PCSK9 inhibitors, including monoclonal antibodies such as evolocumab and alirocumab, have revolutionized lipid-lowering therapy by enabling profound reductions in LDL-C levels, with a corresponding significant decrease in MACE [145,146].”
Wang, Q., Liu, Z., Zhou, W., Wu, G., Hu, K., Su, H., Yan, J., & Chen, K. (2025) · Scientific Reports · doi:10.1038/s41598-025-24832-9 · Cited by 6
“However, these recommendations are primarily derived from evidence in patients with ASCVD 17–19 , and their applicability to HF, particularly HFrEF, remains uncertain.”
Stevens, C. A. T., Smith, J. L., Brandts, J., Barkas, F., Morales, M. M., Janani, L., Kiru, G., Kaza, N., Cornelius, V. R., Poulter, N. R., et al. (2025) · European Heart Journal - Digital Health · doi:10.1093/ehjdh/ztaf135 · Cited by 5
Targeting Vulnerable Plaques in Coronary Artery Disease: Detecting Risk, Preventing Events
Kakizaki, R., Bär, S., & Räber, L. (2025) · Current Cardiology Reports · doi:10.1007/s11886-025-02302-y · Cited by 4
“After 9–12 months, the combination group had a significantly greater reduction in PAV than the atorvastatin-alone group (–1.4% [–3.4 to − 0.1] vs. − 0.3% [–1.9 to 0.9], p = 0.001) [26 ].”
InfluentialAudehm, R. G., Liew, D., Watts, G. F., Hespe, C. M., Rahman, M., Williamson, A. E., Sciascia, C., Santani, R., & Tonkin, A. M. (2025) · Heart Lung and Circulation · doi:10.1016/j.hlc.2025.07.012 · Cited by 3
Jalal, A. A., Hussain, S. I., Siddiqui, E., Khan, M. S., Burhan, M., Karim, A. J., Nizam, R., & Amir, M. (2025) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001789 · Cited by 3
PCSK9 in Cancer: Biological Mechanisms and Implications for Therapeutic Resistance
Azmi, N. U., Syahdi, R. R., Puteri, M. U., Yanuar, A., Kato, M., & Saputri, F. C. (2025) · Biomolecules · doi:10.3390/biom16010067 · Cited by 3
“Cardiovascular outcomes trials further demonstrated cardiovascular risk reduction with PCSK9 monoclonal antibodies in high-risk patients [16,17].”
Kim, J., Park, D., Yoo, J., Kim, J. E., Kim, E. E., & Bang, O. Y. (2026) · Stroke · doi:10.1161/strokeaha.125.052894 · Cited by 4
Wang, S., Li, C., & Fan, D. P. (2026) · Cardiovascular Therapeutics · doi:10.1155/cdr/6345873 · Cited by 3
“Finally, though evolocumab and alirocumab demonstrated proven cardiovascular risk reduction in multiethnic cohorts [44 – 46], the cardiovascular ben-e fi t pro fi les of these novel agents remain undetermined.”
Bouillet, B., Boulestreau, R., Aboyans, V., Béliard, S., Boccara, F., Cariou, B., Charrière, S., Moulin, P., Vergès, B. L., Valéro, R., et al. (2026) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2026.01.001 · Cited by 2
Adjunctive pharmacological strategies for residual risk reduction after myocardial revascularisation
Oshima, A., Serruys, P. W. J. C., Garg, S., McEvoy, J. W., Wood, D., Doenst, T., Taggart, D. P., Puskas, J. D., Shajahan, A., Sharif, F., et al. (2026) · EuroIntervention · doi:10.4244/eij-d-25-00598 · Cited by 5
Kamrul-Hasan, A. B. M., Mahajan, K., Khalil, I., Shahriar, N., Nagendra, L., Dutta, D. J., & Pappachan, J. M. (2026) · Endocrine Practice · doi:10.1016/j.eprac.2026.02.002 · Cited by 5
Li, X., Elebring, M., Heijer, M., Vega, R. B., Rudvik, A., Singh, N. K., Simmonds, R., Pelay-Gimeno, M., Reinen, J., Vedin, C., et al. (2026) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.70162 · Cited by 2
“14,15 To date, approved PCSK9 inhibitors include two monoclonal antibodies and a small interfering RNA medicine, which are dosed via subcutaneous injection.”
Impact of Lipoprotein(a) on Residual Cardiovascular Risk After an Acute Coronary Syndrome
González-Aguado, N., Franco-Hita, R., Larrubia-Valle, J. I., Puyol-Ruiz, F., Mezcua, A. R., García‐Pinilla, J. M., Jiménez-Salva, M., Piserra‐López, A., Pavón, F. J., Pérez-Cabeza, A., et al. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15051688 · Cited by 2
“…(RCTs), such as the ODYSSEY Outcomes trial, which evaluated the Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) inhibitor alirocumab in patients following an ACS, has demonstrated that despite achieving intensive LDL-C control, residual risk of cardiovascular events remains substantial [2].”
InfluentialZhu, B., Liao, Y., Yu, Q., Lui, D. T. W., Wong, E. C.-K., Chan, E. W., Chui, C. S. L., & Blais, J. E. (2026) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwag122 · Cited by 2
Katzmann, J. L., & Laufs, U. (2026) · Current Atherosclerosis Reports · doi:10.1007/s11883-026-01390-7 · Cited by 2
Matteucci, A., Fusco, S. A. D., Bonanni, M., Marino, G., Fedele, S., Nardi, F., & Colivicchi, F. (2026) · Journal of clinical lipidology · doi:10.1016/j.jacl.2026.02.018 · Cited by 5
Kafol, J., Fras, Z., Novaković, M., Sperling, L. S., Cevc, M., Krevel, B., Kafol, L., Kelenc, A., Kepic, K., Vrbinc, K. N., et al. (2026) · Lipids in Health and Disease · doi:10.1186/s12944-026-02897-3 · Cited by 3
“All three agents have demonstrated robust LDL-C lowering and excellent tolerability, while the monoclonal antibodies have additionally shown significant reduction of cardiovascular events [13–15].”
InfluentialMehta, V., Agarwal, N., Mehra, P., Mehta, N., Yusuf, J., Dabla, P. K., Sukhija, S., Safal, S., Gupta, M., Kumar, S., et al. (2026) · Journal of the Association of Physicians of India · doi:10.59556/japi.74.1444 · Cited by 3
Oterino, A., Olmo, R. F., Toro, M. M., & Cordero, A. (2026) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2026.120714 · Cited by 2
Iribarren, C., Lu, M., Go, A. S., Rana, J. S., Ngai, K., & Rogers, A. M. (2026) · American Heart Journal · doi:10.1016/j.ahj.2026.107430 · Cited by 3
Sex Differences in Statin Intolerance: Insights From the CLEAR Outcomes Trial
Naderi, S., Brennan, D. M., Li, N., Lincoff, A. M., Nicholls, S. J., Nissen, S. E., Plutzky, J., Powell, H. A., Robinson, P. L., & Cho, L. (2026) · Clinical Cardiology · doi:10.1002/clc.70288 · Cited by 3
From biology to imaging: Rethinking vulnerable plaques in coronary artery disease
Elia, E., Carbone, F., Lombardi, M., Demarchi, A., Malfa, G. L., Fiorentini, V., Audo, A., Maj, G., Montecucco, F., Patti, G., et al. (2026) · European Journal of Clinical Investigation · doi:10.1111/eci.70202 · Cited by 2
“66 At the structural level, LLDs stabilize vulnerable plaques, as OCT demonstrates increased fibrous cap thickness, fewer TCFAs, and reduced macrophage infiltration.”
Current and emerging approaches to managing peripheral artery disease: a specialist review
Mohammadi, A., Hussein, L., Yahyavi, A., & Shishehbor, M. H. (2026) · Heart · doi:10.1136/heartjnl-2025-326532 · Cited by 4
Tu, Z., Wei, Y., Liao, Y., Wan, Z., Zhou, Z., & Guo, J. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1816199 · Cited by 3
Pedretti, R. F. E., Craenenbroeck, E. M. V., Vrints, C., Ambrosetti, M., Kurpas, D., Vassiliou, V. S., Bäck, M., Moholdt, T. T., Sionís, A., Wilhelm, M., et al. (2026) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwag236 · Cited by 7
Yang, W., Song, T., Koh, S.-H., Jeong, H. S., Sohn, S., Kim, Y. W., Kim, B., Jung, J., Jung, K., Kim, J., et al. (2026) · Journal of the American Heart Association · doi:10.1161/jaha.125.046824 · Cited by 2
“Current guidelines recommend an LDL-C target of 70 mg/dL for patients with ischemic stroke attributable to large artery atherosclerosis, 7 based on findings from the TST (Treat Stroke to Target) trial.”
Oral PCSK9 inhibitors for elevated LDL-C: A systematic review and meta-analysis of randomized trials
Karthikeyan, A., Karp, A., Maliha, M., Kharawala, A., Mangalesh, S., Shah, P., Modak, V., Alper, A., Doshi, A., Murli, H., et al. (2026) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2026.101659 · Cited by 2
“Not all lipid fractions track equally with PCSK9 inhibition, with this variability most notable in Lp(a), paralleling the pattern previously reported with injectable PCSK9 inhibitors [2,3].”
InfluentialAre we underestimating the benefits of lipid-lowering therapies?
Pirillo, A., Casula, M., Olmastroni, E., Scotti, S., Corsini, A., & Catapano, A. L. (2026) · Pharmacological Reviews · doi:10.1016/j.pharmr.2026.100140 · Cited by 2
Knowlton, K. U., Návar, A. M., Anderson, J. L., Brown, A. S., Muhlestein, J. B., Kleeman, K., Sarwat, S., Abbas, C. A., Ramirez, M. A., Grines, C. L., et al. (2026) · Journal of the American Heart Association · doi:10.1161/jaha.125.043655 · Cited by 7
“18,19 Despite clinical trial evidence supporting LLT intensification, 18–22 as well as medical society recommendations, 50% of patients achieve LDL-C 70 mg/dL within 90 days and 1 year of ACS, and treatment gaps to improve goal attainment remain.”
Dyslipidaemias in cancer patients
Nazir, M. S., Cegla, J., Andrés, M. S., Ray, K. K., & Lyon, A. R. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag265 · Cited by 2
Mauriello, A., Falco, A. D., Correra, A., D’Andrea, A., Giallauria, F., Giordano, A., & Russo, V. (2026) · Current Atherosclerosis Reports · doi:10.1007/s11883-026-01414-2 · Cited by 2
“Reduced LDL receptor availability decreases LDL-C clearance, whereas monoclonal antibodies against PCSK9 can lower LDL-C by up to 57% as monotherapy and up to 73% when combined with statins [104, 105].”
Wang, Y., Zhang, Y., Bao, Z., Li, D., Jafari, S. M., & Pan, Q. (2026) · Advances in Colloid and Interface Science · doi:10.1016/j.cis.2026.103963 · Cited by 2
FNIP1 variants are associated with favourable metabolism in 1 million humans
Hindy, G., Adam, R. C., Sosina, O. A., Pryce, D. S., Blair, D., Herman, J., Lee, J., Dornbos, P., Mayerhofer, E., Gilly, A., et al. (2026) · Nature · doi:10.1038/s41586-026-10864-2 · Cited by 3
“27), which encodes another member of the folliculin pathway with functions that have been hypothesized to be similar to those of FNIP1.”
InfluentialGiugliano, R. P., Bohula, E. A., Bellavia, A., Ferrari, G. M. D., Leiter, L. A., Nicolau, J. C., Bhatia, A. K., Murphy, S. A., Liu, L., Wang, H., et al. (2026) · Circulation · doi:10.1161/circulationaha.126.082436 · Cited by 2
Armario, P., Brotons, C., Elosúa, R., de Leciñana, M. A., Castro, A., Clarà, A. B. I., Cortés, O., Rodríguez, Á. D., Herranz, M., Justo, S., et al. (2021) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2020.11.004 · Cited by 7
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in the treatment of dyslipidemia
Shikaleva, А. А., Maksimov, М. L., & Kiseleva, N. M. (2021) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2020-21-12-18 · Cited by 2
Xiong, T., Qian, A. S., & Trigatti, B. L. (2021) · Vessel Plus · doi:10.20517/2574-1209.2020.71 · Cited by 2
“Indeed, two monoclonal antibodies against PCSK9 (evolocumab and alirocumab), have shown potent cholesterol lowering effects and reduced CVEs in large clinical studies([13,14]).”
BackgroundPerception of food allergy among mothers of allergic children in Southwestern Saudi Arabia
Alqahtani, Y. A., Shati, A. A., Alhanshani, A. A., Hanif, B. M., Salem, E. S., M., A. M. A., & Asseri, A. A. (2021) · World Family Medicine Journal/Middle East Journal of Family Medicine · doi:10.5742/mewfm.2021.93988 · Cited by 2
Nanna, M. G., Peterson, E. D., Chiswell, K., Overton, R. A., Nelson, A. J., Kong, D. F., & Návar, A. M. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2021.02.004 · Cited by 2
“We sought to: 1) determine which, if any, angiographic features were most predictive of downstream ASCVD events; and 2) assess the degree to which these angiographic features improve the discrimination of models based on baseline clinical factors alone.”
BackgroundInfluentialTara, S., Takeshi, Y., Sakai, S., Kimura, T., Kazuhiro, A., Fujimoto, Y., Shiomura, R., Junya, M., Kadooka, K., Kenta, T., et al. (2021) · Journal of Nippon Medical School · doi:10.1272/jnms.jnms.2021_88-601 · Cited by 4
Cardiologist's approach to the diabetic patient: No further delay for a paradigm shift
Maranta, F., Cianfanelli, L., Gaspardone, C., Rizza, V., Grippo, R., Ambrosetti, M., & Cianflone, D. (2021) · International Journal of Cardiology · doi:10.1016/j.ijcard.2021.05.050 · Cited by 2
Jin, S., Nie, X., Li, Y., Yuan, J., Cui, Y., & Zhao, L. (2021) · Clinical Therapeutics · doi:10.1016/j.clinthera.2021.04.019 · Cited by 2
Gene Silencing Therapeutics in Cardiology: A Review Article
Jay, P. Y., Maier, M. A., Saltonstall, L., Duarte, L., Antonino, I., & Vest, J. (2021) · International Journal of Cardiovascular Sciences · doi:10.36660/ijcs.20200306 · Cited by 3
Intensive lipid-lowering therapy, time to think beyond low-density lipoprotein cholesterol
Abdalwahab, A., Al‐Atta, A., Zaman, A., & Alkhalil, M. (2021) · World Journal of Cardiology · doi:10.4330/wjc.v13.i9.472 · Cited by 2
Hoang, S. V., Pham, Q. D. D., Nguyen, K. M., Huynh, K., Ngo, T. T., Minh, L. H. N., & Tran, H. P. N. (2022) · Biomedical Research and Therapy · doi:10.15419/bmrat.v9i1.724 · Cited by 2
Shining a Light on Plaque Vulnerability and Treatment
Stone, G. W., & Narula, J. (2022) · JACC. Cardiovascular imaging · doi:10.1016/j.jcmg.2022.04.019 · Cited by 2
Loutradis, C., Sarafidis, P. A., Ortíz, A., & Ferro, C. J. (2022) · SN Comprehensive Clinical Medicine · doi:10.1007/s42399-022-01242-w · Cited by 2
“Interestingly however, both evolocumab and alirocumab (PCSK9 inhibitors) reduce Lp(a) levels by approximately 25% [35, 44], and the reduction is associated with prevention of future major cardiovascular events [45].”
BackgroundSudano, I., Mach, F., Moccetti, T., Burkard, T., Fahe, C., Delabays, A., Rickli, H., Keller, P., Dopheide, J. F., Bodenmann, S., et al. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.953040 · Cited by 2
“In the largest trial of this program, the ODYSSEY OUTCOMES study, treatment with alirocumab significantly reduced the rate of major adverse cardiovascular events (MACE) and was associated with a lower mortality of any cause in almost 19,000 patients after acute coronary syndrome (5).”
BackgroundResultRott, D., Hay, I., Nabutovsky, I., et al. (2022) · International Journal of Cardiology Cardiovascular Risk and Prevention · doi:10.1016/j.ijcrp.2022.200145 · Cited by 2
Cardiac Alarmins as Residual Risk Markers of Atherosclerosis under Hypolipidemic Therapy
Șuică, V. I., Uyy, E., Ivan, L., Boteanu, R. M., Cerveanu‐Hogas, A., Hansen, R., & Antohe, F. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911174 · Cited by 2
“Therefore, an argument in favor of a synergistic statin and PCSK9 inhibition therapy was postulated and readily confirmed in several medical studies [4,9,10].”
ResultReducing cardiovascular risk in patients with type 2 diabetes mellitus
Ahmed, W., Vahabi, S., & Zaman, A. (2022) · Medicine · doi:10.1016/j.mpmed.2022.08.001 · Cited by 2
Randomized Trials Fit for the 21st Century
Bowman, L. J., Weidinger, F. F., Albert, M. A., et al. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2022.12.001 · Cited by 2
Continuous Improvement of Antiplatelet Therapy in Cardiovascular Disease
Verheugt, F. W. A., & Huber, K. (2023) · Thrombosis and Haemostasis · doi:10.1055/s-0042-1760129 · Cited by 2
Challenges with PCSK9 Inhibitors Use in Asia Given Real-World Data Implications
uno, K. (2023) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.ed230 · Cited by 3
Akiyama, T., Ozaki, K., Takano, T., Yoneyama, S., Kubota, N., Okubo, T., Ikegami, R., Hoyano, M., Yanagawa, T., & Inomata, T. (2023) · Internal Medicine · doi:10.2169/internalmedicine.1609-23 · Cited by 2
Yasuda, Y., Ishiguchi, H., Yamaguchi, M., Murakami, K., Kinoshita, N., Kato, T., Yoshida, M., Imoto, K., Sonoyama, K., Kawabata, T., et al. (2023) · Circulation Reports · doi:10.1253/circrep.cr-23-0029 · Cited by 3
Matthias, A. T., Ekanayake, R., & Arambepola, C. (2022) · International Journal of Noncommunicable Diseases · doi:10.4103/jncd.jncd_14_22 · Cited by 2
Metadata
- Authors
- Schwartz, G. G., Steg, P. G., Szarek, M., Bhatt, D. L., Bittner, V. A., Diaz, R., Edelberg, J. M., Goodman, S. G., Hanotin, C., Harrington, R. A., Jukema, J. W., Lecorps, G., Mahaffey, K. W., Moryusef, A., Pordy, R., Quintero, K., Roe, M. T., Sasiela, W. J., Tamby, J.-F., Tricoci, P., White, H. D., & Zeiher, A. M.
- Affiliations
- Inserm (FR)
- From the Division of Cardiology, University of Colorado School of Medicine, Aurora (G.G.S.); Assistance Publique–Hôpitaux de Paris, Hôpital Bichat, Paris Diderot University, Sorbonne Paris Cité, FACT (French Alliance for Cardiovascular Trials), and INSERM Unité 1148 (P.G.S.), and Sanofi (C.H., G.L.) — all in Paris; the National Heart and Lung Institute, Imperial College, Royal Brompton Hospital, London (P.G.S.); the State University of New York Downstate School of Public Health, Brooklyn (M.S.), and...
- State University of New York (US)
- Brigham and Women's Hospital (US)
- St. Michael's Hospital (CA)
- Goethe University Frankfurt (DE)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-11-29
- Volume
- 379
- Issue
- 22
- Pages
- 2097-2107
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2899997727
- Semantic Scholar
- 3bd18f4d47c498a70a737151f3b2a9a1a09050bd
- Cited by
- 3,634
- References
- 22
- Citations by year
- 2026: 452 · 2025: 403 · 2024: 450 · 2023: 446 · 2022: 471 · 2021: 473 · 2020: 481 · 2019: 414 · 2018: 31
- FWCI
- 363.89
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
- SZTE Publicatio Repozitórium (University of Szeged) (acceptedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- Leiden Repository (Leiden University) (submittedVersion)
- Lanzhou University Institutional Repository (submittedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- HAL (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Institutional Repositories DataBase (IRDB) (submittedVersion, cc-by-nc-nd)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Lirias (submittedVersion)
- Dspace Repository (Marmara Üniversitesi) (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- Griffith Research Online (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- Sanofi
- Regeneron Pharmaceuticals
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Keywords
- alirocumab, PCSK9 inhibitors, acute coronary syndrome, cardiovascular outcomes, LDL cholesterol lowering, high-intensity statin therapy, LDL cholesterol targets, cardiovascular mortality, myocardial infarction, ischemic stroke, unstable angina, apolipoprotein B, non-HDL cholesterol, secondary prevention, cardiovascular risk reduction, LDL-C lowering therapy
- MeSH terms
- Proprotein Convertase 9, PCSK9 Inhibitors, Adult, Aged, Antibodies, Monoclonal, Anticholesteremic Agents, Cardiovascular Diseases, Double-Blind Method, Female, Follow-Up Studies, Humans, Hypercholesterolemia, Cholesterol, LDL, Male, Middle Aged, Acute Coronary Syndrome, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-08, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-08 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

